VELDONA
Phase 2- Indications
- HIV-associated oral warts, Sjögren's syndrome, COVID-19, Common cold, Influenza
Company intelligence / Profile preview
TCNT is a vertically integrated advanced materials company specializing in carbon nanomaterials such as carbon nanotubes and graphene. It has developed multiple commercialized products including medical devices like rapid COVID‑19 antigen tests and the Biochip® for myocardial infarction risk assessment. The company is also involved in energy storage solutions and composite materials. Clinical validation of its diagnostic platforms is ongoing at major Taiwanese hospitals. Ainos, a subsidiary, develops breath-based POCTs and digital nose technologies.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Taiwan Carbon Nano Technology.